Prescription Drug Affordability Boards (PDABs): What Are They and Why Should Advocates Care about Them?

States are also grappling with the growing state budget impacts of high drug prices and are eager to follow the lead of the federal government in seeking policy solutions to this problem. [...] The criteria the Colorado PDAB will cost effectiveness of a drug or other health use to determine the upper payment is set forth in care intervention – devalues the lives of people regulations, and the PDAB is prohibited from considering with disabilities and/or chronic medical research or methods involving Quality Adjusted Life Years conditions. [...] Cystic fibrosis advocates applauded the decision of the PDAB to ultimately not pursue an upper payment limit for Trikafta, one of the five drugs the PDAB was considering for potential action. [...] Similarly, HIV advocates in the state also urged the PDAB to take Genvoya off of their list, arguing that existence of ADAP and copay assistance programs, coupled with the fact that there are more alternatives to Genvoya than there had been in the past, means that the drug is in fact 3 . [...] The nuanced policy debate on whether an upper payment limit was appropriate for these two drugs, however, has shone a spotlight on the complex dynamics of the drug pricing ecosystem and the way safety net providers and programs operate within it.